Myeloproliferative and thrombotic burden and treatment outcome of thrombocythemia and polycythemia patients

• 作者: Jan Jacques Michiels
• 来源期刊: 世界重症医学杂志
• 学科: 医学
• 关键词: MYELOPROLIFERATIVE neoplasms Essential THROMBOCYTHEMIA POLYCYTHEMIA VERA JAK2^V617F mutation Aspirin Interferon HYDROXYUREA
• 年，卷（期）: 2015,（3）
• 页码范围: 230-239
• 页数: 10页
• 分类号: R

摘要

Prospective studies indicate that the risk of microvascular and major thrombosis in untreated thrombocythemia in various myeloproliferative neoplasms(MPN-T)is not age dependent and causally related to platelet-mediated thrombosis in early,intermediate and advanced stages of thrombocythemia in MPN-T.If left untreated both microvascular and major thrombosis frequently do occur in MPN-T,but can easily be cured and prevented by low dose aspirin as platelet counts are above 350×109/L.The thrombotic risk stratification in the retrospective Bergamo study has been performed in 100 essential thrombocythemia(ET)patients not treated with aspirin thereby overlooking the discovery in 1985 of aspirin responsive platelet-mediated arteriolar and arterial thrombotic tendency in MPN-T disease of ET and polycythemia vera(PV)patients.The Bergamo definition of high thrombotic risk and its persistence in the 2012 International Prognostic Score for ET is based on statistic mystification and not applicable for low and intermediate MPN-T disease burden in ET and PV patients on aspirin.With the advent of molecular screening of MPN patients,MPN-T disease associated with significant leukocytosis,thrombocytosis,constitutional symptoms and/or moderate splenomegaly are candidates for low dose peglyated interferon(Pegasys^R,45 mg/mL once per week or every two weeks)as the first line myeloreductive treatment option in JAK2^V617F mutated MPN-T disease in ET and PV patients.If non-responsive to or side effects induced by IFN,hydroxyurea is the second line myelosuppressive treatment option in JAK2V617F mutated ET and PV patients with increased MPN-T disease burden.